logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
05/06/2025
Victoria's Secret's stock price has risen by about 2%, and the company's preliminary performance for the first quarter is optimistic.
Latest
2 m ago
The increase in steel and aluminum tariffs will push up prices of various goods, some by several thousand dollars.
3 m ago
Hengrui Medicine: Citrate Sodium Blood Filtration Replacement Solution Approved for Market Launch
3 m ago
Hong Kong Hang Seng Index rose by 1.07%. Hang Seng Tech Index rose by 1.93%.
3 m ago
The Hang Seng Index closed up 1.07%, with consumer stocks generally pulling back.
3 m ago
Hengrui Medicine announced that its subsidiaries Suzhou Shendia Biopharmaceutical Co., Ltd. and Shanghai Shendi Pharmaceutical Co., Ltd. have received approval from the National Medical Products Administration to conduct clinical trials for the injection SHR-A1811, the Adabelli monoclonal antibody injection, and the sorafenib apple acid capsule. The clinical trials will begin soon. The injection SHR-A1811 will be used in combination with anti-tumor drugs for the treatment of solid tumors in an open, multi-center phase Ib/II clinical study. The sorafenib apple acid capsule will be used in combination with the injection of carrizumab monoclonal antibody for the treatment of recurrent or metastatic cervical cancer patients who have previously failed platinum-based chemotherapy but have not received treatment with bevacizumab monoclonal antibody. Up to now, the total research and development investment in the injection SHR-A1811 project is about 1.17 billion yuan, in the Adabelli monoclonal antibody injection project about 815 million yuan, and in the sorafenib apple acid capsule project about 255 million yuan.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.